Trombin-receptor antagonist vorapaxar in acute coronary syndromes

Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216208%3A11120%2F12%3A00003513" target="_blank" >RIV/00216208:11120/12:00003513 - isvavai.cz</a>
Alternative codes found
RIV/00064173:_____/12:#0000107
Result on the web
<a href="http://dx.doi.org/10.1056/NEJMoa1109719" target="_blank" >http://dx.doi.org/10.1056/NEJMoa1109719</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1056/NEJMoa1109719" target="_blank" >10.1056/NEJMoa1109719</a>

Result language
angličtina
Original language name
Trombin-receptor antagonist vorapaxar in acute coronary syndromes
Original language description
Vorapaxar is a new oral protease-activated-receptor 1 (PAR-1) antagonist that inhibits thrombin-induced platelet activation. In this multinational, double-blind, randomized trial, we compared vorapaxar with placebo in 12,944 patients who had acute coronary syndromes without ST-segment elevation. The primary end point was a composite of death from cardiovascular causes, myocardial infarction, stroke, recurrent ischemia with rehospitalization, or urgent coronary revascularization. In patients with acute coronary syndromes, the addition of vorapaxar to standard therapy did not significantly reduce the primary composite end point but significantly increased the risk of major bleeding, including intracranial hemorrhage. (Funded by Merck; TRACER ClinicalTrials.gov number, NCT00527943.).
Czech name
—
Czech description
—

Type
J<sub>x</sub> - Unclassified - Peer-reviewed scientific article (Jimp, Jsc and Jost)
CEP classification
FA - Cardiovascular diseases including cardio-surgery
OECD FORD branch
—

Publication year
2012
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Similar results(10)